Edition:
United States

Abiomed Inc (ABMD.OQ)

ABMD.OQ on NASDAQ Stock Exchange Global Select Market

195.59USD
20 Nov 2017
Change (% chg)

-- (--)
Prev Close
$195.59
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
123,146
52-wk High
$200.00
52-wk Low
$103.55

Summary

Name Age Since Current Position

Michael Minogue

50 2005 Chairman of the Board, President, Chief Executive Officer

Ian McLeod

2017 Principal Financial Officer, Principal Accounting Officer, Vice President, Controller

David Weber

55 2007 Chief Operating Officer

William Bolt

65 2015 Senior Vice President, Global Quality, Regulatory and Clinical Operations

Andrew Greenfield

44 2014 Vice President, General Manager - Global Marketing

Michael Howley

53 2009 Vice President, General Manager - Global Sales and Marketing

Dorothy Puhy

65 2005 Lead Independent Director

Jeannine Rivet

69 2016 Independent Director

Eric Rose

66 2014 Independent Director

Martin Sutter

62 2008 Independent Director

Henri Termeer

71 1987 Independent Director

Paul Thomas

61 2011 Independent Director

Christopher Van Gorder

64 2016 Independent Director

Biographies

Name Description

Michael Minogue

Mr. Michael R. Minogue is the Chairman of the Board, President, Chief Executive Officer of Abiomed, Inc. He has served as our Chief Executive Officer, President and a director since April 2004. In June 2005, he was appointed Chairman of our Board of Directors. Prior to joining us, Mr. Minogue had a twelve-year career at General Electric, or GE. Most recently, Mr. Minogue was Vice President and General Manager of Americas Sales and Marketing for GE Medical Systems Information Technology. From 1997 to 2004, Mr. Minogue held various positions at GE, including General Manager for the Global Positron Emission Technology Business, General Manager, Americas Cardiology & IT Sales and General Manager, Global Installed Base. Prior to joining GE, Mr. Minogue served on active duty for four years as an infantry officer in the U.S. Army and received multiple awards. Mr. Minogue received his Bachelor of Science in Engineering Management from the United States Military Academy at West Point and his Master of Business Administration from the University of Chicago. Mr. Minogue currently serves on the Board of Directors of the Advanced Medical Technology Association and also serves as a Manager on the Board of Managers of Bioventus LLC, a strategic partnership between EW Healthcare Partners and Smith & Nephew plc, a global medical technology business based in the United Kingdom. Mr. Minogue is also the Chair of the Board of Directors of the Medical Device Innovation Consortium, a public-private partnership created with the objective of advancing medical device regulatory science. He was formerly on the Board of Directors of LifeCell Corporation, which was acquired by Kinetic Concepts, Inc. in May 2008.

Ian McLeod

David Weber

Dr. David M. Weber is the Chief Operating Officer of the Company. Dr. Weber joined us in April 2007 as our Chief Operating Officer. Prior to joining us, Dr. Weber served as General Manager, Aviation Business at GE Security—Homeland Protection from April 2005 until April 2007 where he led GE Security’s Aviation and Transportation Business and was responsible for product development, marketing and sales. From June 2004 until April 2005, he served as General Manager, MRI Marketing at GE Healthcare where he was responsible for strategic product planning, go-to-market and product launch activities, including developing product roadmaps and introducing new product technologies to the market, and from March 2001 until June 2004, he served as Manager, Global High Field MRI Business, GE Medical Systems where he was responsible for new product planning and development. Dr. Weber has a Bachelor of Science in physics from Denison University, a Bachelor of Science in Nuclear Engineering from Columbia University, a Master of Science in Medical Physics from the University of Wisconsin, and a Doctor of Philosophy in Medical Physics from the University of Wisconsin.

William Bolt

Mr. William J. Bolt is the Senior Vice President, Global Quality, Regulatory and Clinical Operations of Abiomed, Inc. He joined us in June 1982 and has served as our Senior Vice President of Quality, Regulatory & Clinical Research Operations since 2015. He is currently responsible for all product development, management, engineering, regulatory, clinical and quality functions. From 2010 to 2015, Mr. Bolt held the position of Senior Vice President of Global Product Operations. From 2006 to 2009, Mr. Bolt was responsible, at different times, for quality, regulatory and engineering functions at the Company. From 2003 to 2006, he was responsible for our quality and service functions. He was responsible for all product development and the AbioCor program from 2000 to 2003, and for BVS and AB5000 development from 1999 to 2003. From 1994 to 1999, he was President of our former dental subsidiary, ABIODENT. From 1982 to 1994, he served in various roles, from Vice President of Engineering to Vice President of Operations. Mr. Bolt received both his Bachelor of Science in Electrical Engineering and Master of Business Administration from Northeastern University.

Andrew Greenfield

Mr. Andrew J. Greenfield is the Vice President, General Manager - Global Marketing of Abiomed, Inc. Since joining us in 2005 as the Vice President of Healthcare Solutions, he has led the reimbursement and health economics organizations. Mr. Greenfield also leads the global marketing function and is responsible for physician education programs, new market development, and service. Before joining us, Mr. Greenfield held positions in sales, marketing and finance at GE Healthcare including consulting with large U.S. health systems, eCommerce and Six Sigma from 1999 to 2005. Prior to GE Healthcare, he held positions in sales, marketing and finance at The Boeing Company, including European Country Manager, and is a graduate of the Fiscal Development Program. He received his Bachelor degree in Finance from the University of Illinois in 1994 and a Master of Business Administration degree from St. Louis University in 1998. Mr. Greenfield is also a certified Master Blackbelt in Six Sigma and Change Acceleration Process from General Electric.

Michael Howley

Mr. Michael G. Howley is the Vice President, General Manager - Global Sales of Abiomed, Inc., since March, 2009. Prior to joining us, Mr. Howley spent 20 years at GE Healthcare. From February 2006 to February 2009, he was General Manager at GE Healthcare, overseeing the Americas X-ray and Interventional Radiology division. From April 2004 to February 2006, Mr. Howley held the General Manager position for the Clinical Information Systems at GE. From October 2002 to April 2004, he was the Americas Sales Manager of Functional and Molecular Imaging. Prior to this role, Mr. Howley held several other national and regional sales positions at GE, beginning in 1989. Mr. Howley has a Bachelor of Science in Business Administration and Marketing from Auburn University.

Dorothy Puhy

Ms. Dorothy E. Puhy is the Lead Independent Director of Abiomed, Inc. Ms. Puhy has served as a director since August 2003 and as our Lead Director since October 2005. Ms. Puhy has served as Executive Vice President and Chief Operating Officer for the Dana-Farber Cancer Institute since 2012. Ms. Puhy previously served as the Chief Financial Officer of the Dana-Farber Cancer Institute from 1994 to 2012 and as its Assistant Treasurer from 1995 to 2012. From 1985 to 1994, Ms. Puhy held various financial positions at the New England Medical Center Hospitals, Inc., including Chief Financial Officer from 1989 to 1994. Ms. Puhy is also a director of Eaton Vance Corp. Ms. Puhy received her Bachelor of Arts from the University of Pennsylvania and her Master of Business Administration from the Wharton School of Business at the University of Pennsylvania.

Jeannine Rivet

Ms. Jeannine M. Rivet is an Independent Director of the Company. Ms. Rivet has served as a director since February 2016. Ms. Rivet has served as Executive Vice President of UnitedHealth Group since 2001. Previously at UnitedHealth Group, she served as Chief Executive Officer of UnitedHealthcare from 1998 to 2001, Chief Executive Officer of Ingenix from 2001 to 2003 and Chief Executive Officer of Optum from December 2003 to 2005. She currently serves as an advisory board member to Solutran, a customized treasury management company, and was a member of the board of Schwan Food Company from 2000 to April 2016. Ms. Rivet received a Bachelor of Science in Nursing from Boston College and a Master’s Degree in Public Health from Boston University. She also worked as a registered nurse for several years prior to entering the managed care business.

Eric Rose

Dr. Eric A. Rose, M.D. is an Independent Director of the Company. Dr. Rose has served as a director since August 2014 and previously served as a director from May 2007 to January 2012. He serves as Executive Chairman of SIGA Technologies, Inc., a developer of anti-viral drugs directed at potential agents of bioterror that filed voluntary proceedings under Chapter 11 of the United States Bankruptcy Code in September 2014 and exited from bankruptcy protection in April 2016. Dr. Rose served from 2007 to 2016 as Executive Vice President for Life Sciences at MacAndrews & Forbes and Chief Executive Officer of SIGA Technologies, Inc. Dr. Rose chaired the Department of Health Evidence & Policy at the Mount Sinai School of Medicine from 2008 to 2012, where he now serves as professor. From 1994 to 2007, he was Surgeon-in-Chief at New York-Presbyterian Hospital/Columbia and Chairman of the Department of Surgery at the Columbia University College of Physicians and Surgeons. A heart surgeon, researcher and entrepreneur, Dr. Rose helped grow Columbia’s Department of Surgery over the past 25 years while investigating, managing and developing complex medical technologies such as heart transplantation and new approaches to Alzheimer’s disease and bioterrorism. He has authored or co-authored more than 300 scientific publications and has received more than $25 million in NIH support for his research. Dr. Rose pioneered heart transplantation in children, performing the first successful pediatric heart transplant in 1984, and has investigated many alternatives to heart transplantation, including cross-species transplantation and man-made heart pumps. He received both his undergraduate and medical degrees from Columbia University.

Martin Sutter

Mr. Martin P. Sutter is an Independent Director of the Company. has served as a director since May 2008. Since 1985, Mr. Sutter has been the Co-Founder and a Managing Director of EW Healthcare Partners, previously known as Essex Woodlands Health Ventures, a healthcare focused growth equity firm. Educated in chemical engineering and finance, Mr. Sutter has more than 30 years of management experience in operations, marketing, finance and venture capital. Mr. Sutter has been directly involved with more than 30 of EW Healthcare Partners’ portfolio investments, and has served on numerous past Boards of Directors on public and private companies including ATS Medical which was acquired by Medtronic, Inc., BioForm Medical which was acquired by Merz GmbH & Co KGaA, Lifecell which was acquired by Kinetic Concepts, Inc., St. Francis Medical which was acquired by Kyphon, Inc./Medtronic, Inc., Confluent Surgical which was acquired by Tyco International/Covidien and Rinat Neurosciences which was acquired by Pfizer, Inc. He currently serves on the Board of Managers of Bioventus LLC, an orthobiologic solutions company which is a strategic partnership between EW Healthcare Partners and Smith & Nephew plc, a global medical technology business based in the United Kingdom and Xenex Disinfection Services, which offers UV light disinfection solution robots. He also serves on the Board of Directors of Prolacta Bioscience, which provides human milk-based nutritional products for critically ill, premature infants in neonatal intensive care units and QSpex Technologies, Inc., a manufacturer of prescription spectacle lenses. Mr. Sutter holds a Bachelor of Science degree from Louisiana State University, and a Master of Business Administration from the University of Houston.

Henri Termeer

Mr. Henri A. Termeer was an Independent Director of Abiomed, Inc., Prior to Genzyme Corporation’s acquisition in April 2011 by Sanofi, Mr. Termeer was President, and a director of Genzyme Corporation since 1983, its Chief Executive Officer since 1985 and its Chairman since 1988. Mr. Termeer was a member of the Board of Directors of the Massachusetts Institute of Technology, Massachusetts General Hospital and Partners HealthCare. Mr. Termeer was a member of the Board of Fellows of Harvard Medical School. He was also the Chairman of the Board of Aveo Pharmaceuticals and member of the Board of Directors of Verastem, Inc. Mr. Termeer served as the Deputy Chairman of the Federal Reserve Bank of Boston from 2007 to 2009 and as its Chairman from 2010 through the end of 2011. Mr. Termeer studied economics at the Economische Hogeschool at Erasmus University in The Netherlands and received his Master of Business Administration from the Darden School of Business at the University of Virginia. He passed away on May 12, 2017.

Paul Thomas

Mr. Paul G. Thomas is an Independent Director of the Company. Mr. Thomas has served as a director since May 2011. Mr. Thomas served as the founder, president and Chief Executive Officer of Roka Bioscience, Inc. from September 2009 until his retirement in January 2017. Previously he served as Chairman, Chief Executive Officer, and President of LifeCell Corporation from October 1998 until August 2008. Prior to joining LifeCell, Mr. Thomas held various senior positions during a 15-year tenure with the Pharmaceutical Products division of Ohmeda Inc. Mr. Thomas currently serves on the Board of Directors of Roka Bioscience Inc. and RTI Surgical. Mr. Thomas previously served as a member of the board of directors of Aegerion Pharmaceuticals, Inc until its merger with Novelion Therapeutics in 2016. Mr. Thomas received his Bachelor of Science in Chemistry from St. Michael’s College, his Master of Business Administration from Columbia University, and completed his postgraduate studies in chemistry at the University of Georgia.

Christopher Van Gorder

Mr. Christopher D. Van Gorder is an Independent Director of the Company. Mr. Van Gorder has been president and Chief Executive Officer of Scripps Health since 2000, where he has been instrumental in positioning Scripps among the nation's foremost health care institutions. At Scripps Health, Mr. Van Gorder oversees all functions of the integrated health system that has 15,000 employees and 2,600 affiliated physicians, including its five acute-care hospital campuses, dozens of outpatient centers throughout San Diego County, and a regional home health service and hospice. In March 2006, California's governor appointed Mr. Van Gorder, a former police officer, to the California Commission on Emergency Medical Services (EMSA) where he served two terms. In January 2007, U.S. Secretary of State Condoleezza Rice reappointed Mr. Van Gorder to the U.S. Commission for the United Nations Educational, Scientific and Cultural Organization (UNESCO). He is a clinical professor of health practice at the University of Southern California (USC) Price School of Public Policy, where he also serves on the Board of Councilors. Mr. Van Gorder received his master's degree in public administration/health services administration at the University of Southern California, completed the Wharton CEO Program at the University of Pennsylvania and earned his bachelor's degree from California State University, Los Angeles.

Basic Compensation

Name Fiscal Year Total

Michael Minogue

12,219,300

Ian McLeod

--

David Weber

2,734,970

William Bolt

2,168,680

Andrew Greenfield

536,074

Michael Howley

2,296,710

Dorothy Puhy

294,042

Jeannine Rivet

256,542

Eric Rose

259,042

Martin Sutter

266,542

Henri Termeer

259,042

Paul Thomas

269,042

Christopher Van Gorder

261,275
As Of  30 Mar 2017

Options Compensation